Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/204489
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA‐C real‐world cohort |
Autor: | Hernández-Conde, Marta; Fernández Vázquez, Inmaculada; Perelló, Christie; Gallego, Adolfo; Bonacci, Martin; Pascasio, Juan Manuel CSIC; Romero-Gómez, Manuel CSIC ORCID CVN; Llerena, Susana; Fernández-Rodríguez, Conrado M.; Castro Urda, José L.; García-Buey, Luisa; Carmona Soria, Isabel; Morillas, Rosa María; Domínguez García, Nuria; Gea, Francisco; Carrión, José A.; Castellote, José; Moreno-Planas, José M.; Piqueras Alcol, Belén; Molina, Esther; Diago, Moisés; Montoliu, Silvia; Vega, Juan de la; Menéndez, Fernando; Sánchez Ruano, Juan J.; García-Samaniego, Javier; Rosales-Zábal, José Miguel; Antón, María D.; Badía, Ester; Souto‐Rodríguez, Raquel; Salmerón, Javier; Fernández‐Bermejo, Miguel; Figueruela, Blanca; Moreno‐Palomares, José J.; Calleja, José Luis | Palabras clave: | Chronic hepatitis C Elbasvir/grazoprevir Real‐world Spain |
Fecha de publicación: | ene-2019 | Editor: | John Wiley & Sons | Citación: | Journal of Viral Hepatitis 26(1): 55-64 (2019) | Resumen: | In randomized controlled trials of patients with chronic HCV infection, elbasvir/grazoprevir (EBR/GZR) demonstrated high cure rates and a good safety profile. This study assessed the effectiveness and safety of EBR/GZR, with and without ribavirin, in a real‐world HCV patient cohort. HEPA‐C is a collaborative, monitored national registry of HCV patients directed by the Spanish Association for the Study of the Liver and the Networked Biomedical Research Centre for Hepatic and Digestive Diseases. Patients entered into HEPA‐C between December 2016 and May 2017, and treated with EBR/GZR with at least end‐of‐treatment response data, were included. Demographic, clinical and virologic data were analysed, and adverse events (AEs) recorded. A total of 804 patients were included in the study. The majority were male (57.9%), with a mean age of 60 (range, 19‐92) years. Genotype (GT) distribution was GT 1, 86.8% (1a, 14.3%; 1b, 72.5%); GT 4, 13.2% and 176 patients (21.9%) were cirrhotic. Overall, among 588 patients with available data, 570 (96.9%) achieved sustained virologic response at 12 weeks post‐treatment (SVR12). SVR12 rates by genotype were GT 1a, 97.7%; GT 1b, 98.6%; and GT 4, 98.1%. No significant differences in SVR12 according to fibrosis stage were observed. Eighty patients experienced an AE, resulting in treatment discontinuation in three. In this large cohort of patients with chronic HCV managed in a real‐world setting in Spain, EBR/GZR achieved high rates of SVR12, comparable to those observed in randomized controlled trials, with a similarly good safety profile. | Versión del editor: | http://dx.doi.org/10.1111/jvh.13008 | URI: | http://hdl.handle.net/10261/204489 | DOI: | 10.1111/jvh.13008 | ISSN: | 1352-0504 | E-ISSN: | 1365-2893 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 59,24 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
20
checked on 21-abr-2024
WEB OF SCIENCETM
Citations
17
checked on 26-feb-2024
Page view(s)
207
checked on 23-abr-2024
Download(s)
27
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.